| Assessment Status | Rapid Review Complete |
| HTA ID | 24018 |
| Drug | Relugolix with estradiol and norethisterone acetate |
| Brand | Ryeqo® |
| Indication | Relugolix with estradiol and norethisterone acetate (Ryeqo®) is Indicated in adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. |
| Assessment Process | |
| Rapid review commissioned | 28/05/2024 |
| Rapid review completed | 15/07/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of relugolix combination therapy compared with the current standard of care. |
